Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. (NalmeCir)

Centre Hospitalier Universitaire, Amiens

Status and phase: Withdrawn; Phase 3

Conditions: Cirrhosis; Nalmefene; Alcohol Dependence

Treatments: Drug: placebo; Drug: Nalmefene (Selincro®) 18 mg tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT02824354

PI2015_843_0017

Details and patient eligibility

About

Nalmefene is the first drug to obtain Marketing Authorisation in France for reduction of alcohol consumption.

Full description

Nalmefene is the first drug to obtain Marketing Authorisation in France for reduction of alcohol consumption. It appears to be significantly more effective in the group of heavy drinkers, while the mean alcohol consumption in studies conducted in cirrhotic patients is greater than 120 g/day.

No data are available concerning nalmefene in alcohol-dependent patients with alcoholic cirrhosis. However, nalmefene could represent an attractive alternative to reduce heavy drinking in patients with alcoholic cirrhosis, with potential improvement of liver function. No comparator is available for nalmefene, as all other molecules require abstinence prior to starting treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• the patient has signed and dated the informed consent form,

• blood alcohol concentration < 0.02% at the screening visit,

• alcohol-dependent patient according to DSM-IV-TR criteria ,

• patient with compensated cirrhosis (cirrhosis demonstrated by clinical and laboratory and/or morphological examinations and/or by a noninvasive test and/or by liver biopsy), Child A or B,

• patient with at least a high drinking risk level (a moderate risk level is defined as a consumption ≥ 60 g of alcohol/day for men and ≥ 40 g of alcohol/day for women),

• male or female, over the age of 18 years, excluding protected majors,

• patient with a stable address and telephone number,

• name and address of a family member who will be contacted in the event of loss of contact with the patient,

• women of childbearing potential:

  • must accept not to become pregnant during the study and,
  • must use an effective method of contraception (adequate contraception is defined as oral, systemic contraception, intrauterine device, diaphragm in combination with spermicide, or condom for the male partner in combination with spermicide) or,
  • must have had their last natural menstruation ≥ 24 months before the screening visit or,
  • must have been surgically sterilized before the screening visit or,
  • must have undergone hysterectomy before the screening visit or,
  • must have no sexual activity with a male partner

• patient covered by French national health insurance.

Exclusion criteria

• cirrhosis Child Pugh C (decompensated cirrhosis)
• cirrhosis complicated by hepatocellular carcinoma or type I or II hepatorenal syndrome or poorly controlled portal hypertension,
• severe acute alcoholic hepatitis, not responding to corticosteroids by the 7th day defined by a Lille model > 0.56 (www.lillemodel.com/score.asp)
• hepatic encephalopathy during the 6 months preceding the screening visit,
• patient with fewer than 6 heavy drinking days during the 4 weeks preceding the screening visit (a heavy drinking day is defined as alcohol consumption of ≥ 60 g/day for men, and ≥ 40 g/day for women),
• patient with at least 14 consecutive days of abstinence during the 4 weeks preceding the screening visit,
• patient with a CIWA-Ar score (Revised Clinical Institute Withdrawal Assessment for Alcohol) ≥ 10,
• patient with:
• a disorder other than alcohol or nicotine dependence, as evaluated on the MINI (Mini-International Neuropsychiatric Interview)
• antisocial personality disorder evaluated with the MINI questionnaire,
• other disorders for which treatment must take priority to the treatment of alcohol dependence, or which are likely to interfere with the study treatment or compromise adherence to treatment,
• cannabis use does not constitute an exclusion criterion except when it meets the criterion of cannabis dependence
• patient with a suicide risk evaluated using the suicidal tendency module of the MINI (the patient answers "Yes" to one of questions C2, C3, C4, C5 or C6 of the questionnaire),
• patient with a history of delirium tremens or alcohol withdrawal seizures,
• ongoing use of addictive substances other than cannabis, nicotine or benzodiazepines,
• presence of a disorder of comprehension, mental retardation or encephalopathy,
• presence of clinically significant unstable disease (e.g.: renal failure, cardiovascular, pulmonary, gastrointestinal, gastrointestinal, endocrine, neurological, infectious, neoplastic disease or metabolic disorders,
• clinically significant ECG abnormalities,
• history of serious drug allergy or hypersensitivity to nalmefene,
• ongoing or recent treatment (during the 3 months preceding the screening visit) with disulfiram, acamprosate, topiramate, naltrexone, carbimide, or opioid antagonists,
• ongoing or recent treatment (1 week preceding the screening visit) with opioid agonists or partial agonists,
• ongoing or recent treatment (8 weeks preceding the screening visit) with antipsychotics or antidepressants,
• patient taking or who has taken concomitant medications (see supplementary table),
• patient with another disease or taking medications, which, in the investigator's opinion, could interfere with evaluations of safety, tolerability and efficacy,
• treatment with an investigational medicinal product during the 30 days preceding the screening visit,
• ongoing or recent participation (during the 4 weeks preceding the screening visit) in a drinking disorders treatment or support programme, including Alcoholics Anonymous, disintoxication treatment and treatment of alcohol withdrawal symptoms,
• pregnancy or breastfeeding,
• patient who, in the investigator's opinion, has little chance of complying with the protocol or unsuitable for the study for any other reason,
• patient who has already participated in a clinical trial on nalmefene.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Description:

The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with "S" on one side.

Treatment:

Drug: placebo

Nalmefene

Experimental group

Description:

Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with "S" on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate). Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible. The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food.

Treatment:

Drug: Nalmefene (Selincro®) 18 mg tablet